<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185743</url>
  </required_header>
  <id_info>
    <org_study_id>OLA_ZIPRA</org_study_id>
    <nct_id>NCT01185743</nct_id>
  </id_info>
  <brief_title>Antipsychotics and Gene Expression in Soft Tissues</brief_title>
  <official_title>Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a severe chronic and disabling mental disorder and is associated with a
      significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be
      jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid
      metabolism.

      Aim: to gain data on drug related effects on gene expression and regulation with special
      regard to glucose metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gene expression profiling</measure>
    <time_frame>10 days</time_frame>
    <description>To characterize and compare the gene expression profiles in human subcutaneous adipose and muscle tissue prior and after single dose of olanzapine, ziprasidone and placebo.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ziprasidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ziprasidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>olanzapine 10mg od + placebo od</description>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_label>ziprasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone</intervention_name>
    <description>ziprasidone 40mg td</description>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_label>ziprasidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo td</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male.

          -  Healthy, defined as absence of relevant diseases.

          -  Caucasian.

          -  Aged 18-45 years.

          -  Body-Mass-Index (BMI): 18-25 kg/m2.

          -  Signed informed consent.

          -  No signs of impaired glucose tolerance as evaluated by Oral Glucose Tolerance Test
             (OGTT) before study inclusion during screening, normal total cholesterol, High Density
             Lipoprotein (HDL), Low Density Lipoprotein (LDL), triglycerides, normal function of
             the thyroid. No personal or family history (parents and siblings) of diabetes or other
             metabolic and relevant diseases as defined by the investigator.

          -  No indication for psychiatric diseases assessed by structured clinical interview
             (Mini-International Neuropsychiatric Interview (MINI)).

        Exclusion Criteria:

          -  Personal or family history (parents and siblings) of diabetes or other metabolic
             diseases, relevant diseases as defined by the investigator.

          -  History of hypertension, blood pressure &gt; 140/90 at screening, cardiovascular disease.

          -  Body mass index out of the range of &lt;18 and &gt;25 kg/m.

          -  Human immunodeficiency virus (HIV) or Hepatitis B/C positive virology.

          -  Allergy or hypersensitivity against olanzapine/ziprasidone or another excipient.

          -  Contraindications against the use of the drug according to the Summary of Product
             Characteristics (SmPC).

          -  Any drug intake 2 weeks prior to first study day.

          -  History of excessive bleeding tendency/hemophilia.

          -  Presence of relevant illness within the last 3 weeks.

          -  Currently enrolled into an other clinical study with Investigational Medicinal
             Products (IMPs).

          -  Last study participation less than 4 weeks.

          -  Suspected non-compliance with study instructions and life-style requirements.

          -  History of alcohol or drug abuse.

          -  Blood/Plasma donation within 4 weeks prior to study day.

          -  Previous exposure to antipsychotic drugs.

          -  Nicotine consumption at time of enrolment (at least 3 months of non-smoking required).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Brunner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2010</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Martin Bauer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>antipsychotics</keyword>
  <keyword>gene expression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

